Transduction of AAV Vectors in iPSC-Derived Retinal Organoids.

Deborah Aubin, Anai Gonzalez-Cordero

Abstract read

In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Deborah AubinStem Cell Medicine Group, School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia.

Anai Gonzalez-CorderoStem Cell Medicine Group, School of Medical Sciences, Faculty of Medicine and Health, The University of Sydney, Sydney, NSW, Australia. agonzalez-cordero@cmri.org.au.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Stem cell-derived organoids research provides an exciting model and technology to develop new therapies for difficult and intractable diseases. Human-induced pluripotent stem cells (hiPSCs) have the potential to differentiate into organ-like three-dimensional structures, especially when it is challenging to obtain patient samples for this purpose. This chapter outlines a comprehensive differentiation protocol for the generation and manipulation of retinal organoids derived from pluripotent stem cells (PSCs), including embryonic stem cells (ESCs) and hiPSCs. The method involves culturing PSCs, differentiating them into retinal organoids, and in vitro transduction of organoids with adeno-associated virus (AAV) vectors. AAVs can be used to label a desired population, to test novel promoters, and to test gene therapies. We will also describe key steps following organoid transduction, which entail collection, immunostaining, imaging and preservation for molecular biology readouts. The protocol provides a detailed guide for researchers working in the field of retinal biology and gene therapy.

Indexed as

DependovirusGenetic VectorsInduced Pluripotent Stem CellsOrganoidsRetinaTransduction, GeneticCell Culture TechniquesCell DifferentiationHumansAdeno-associated virus (AAV) vectorsDifferentiationGene therapyPluripotent stem cellsRetinal organoidsTransduction

Identifiers

PMID42020907

DOI10.1016/j.stemcr.2017.07.022

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.